Tags · Evidence

effect size

Magnitude, not just direction or significance.

214 topics 77 solved Group: Evidence

Compounds 89 Evidence 84 Research Methods 26 Outcomes 15

214 topics · page 5 of 8

Topic	Participants	Replies	Views	Activity
[2026 update] Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting; the…	+58	63	40k	9mo
Journal club: indirect comparison between two programmes, defended and attacked — one year on Evidence › Journal club randomised trial risk of bias effect size estimand Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N…	+45	50	3k	9mo
Conference abstracts as evidence: the weakest common citation Evidence › Preprints risk of bias effect size needs a source On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+1	5	2k	9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
A preprint whose numbers changed substantially at publication Evidence › Preprints preprint needs a source effect size Wiki Closed A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before posting;…	+90	95	21k	9mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…	+48	52	609	10mo
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP…		2	3.8k	10mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? Evidence › Preprints preprint needs a source effect size Solved Under review The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen LEADER…	+103	115	24k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Reporting a disappointing outcome, and why it belongs here Outcomes › Progress reports data table DXA effect size Closed Reporting a disappointing outcome, and why it belongs here Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a number…	+21	29	62k	10mo
Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold? Evidence › Journal club journal club effect size number needed to treat Solved The question in the title: Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 (…		2	15k	10mo
The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide preprint effect size TRIUMPH programme Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…		2	65k	10mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…	+109	124	31k	10mo
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Evidence › Journal club randomised trial risk of bias effect size number needed to treat Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…	+80	91	10k	11mo
When a preprint is the best available evidence and we say so Evidence › Preprints risk of bias effect size preprint Solved When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+148	160	31k	11mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
Journal club: STEP-HFpEF and symptom endpoints Evidence › Journal club journal club effect size estimand risk of bias Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…	+18	22	2.5k	11mo
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+88	93	29k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…		4	42k	11mo
Risk-of-bias tools and the judgement they conceal Evidence › Meta-analyses meta-analysis heterogeneity publication bias effect size Wiki Risk-of-bias tools and the judgement they conceal Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim I do…	+8	12	21k	11mo
Criticising the method without criticising the authors — one year on Evidence › Study critique confounding effect size disputed risk of bias Solved Closed On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…	+16	20	61k	11mo
Follow-up: What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…		2	25k	11mo
Tirzepatide molecular mass and the charge states you would expect on ESI Compounds › Tirzepatide effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…	+36	40	44k	11mo
Why most self-reports here are not experiments, and that is fine Research Methods › N-of-1 designs confounding worked example data table effect size Closed Why most self-reports here are not experiments, and that is fine — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…		2	46k	11mo
The "under review" status pill and when a moderator applies it — a second dataset Evidence › Preprints needs a source risk of bias preprint effect size The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…	+50	54	1.4k	11mo
[2026 update] Journal club: is percentage weight change the right endpoint? Evidence › Journal club effect size risk of bias randomised trial Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…	+105	118	18k	11mo
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Compounds › Tirzepatide tirzepatide effect size randomised trial Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think…		2	58k	11mo
Multiplicity when you track fifteen variables Research Methods › Statistics effect size heterogeneity confounding worked example Solved Multiplicity when you track fifteen variables — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-OSA ( N Engl J Med , 2024) and finding…		2	60k	11mo